ArticleHeart rhythm O22026
Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HBI-3000 (sulcardine sulfate) inhibits multiple cardiac ion channels in vitro including peak sodium current, late sodium current, L-type calcium current, and the rapid component of the delayed rectifier potassium channel current. Objective: This study aimed to determine electrocardiographic effects, pharmacokinetics, safety, and tolerability of escalating doses of intravenously administered sulcardine in healthy volunteers. Methods: In this first-in-human, randomized, double-blind, placebo-controlled, serial-cohort, dose-escalation study, 47 subjects were randomized to 6 cohorts of 8, each receiving 1 of 5 single ascending 30-minute intravenous infusions (20-600 mg) of HBI-3000 (sulcardine sulfate) or placebo in a 6:2 ratio. Results: Clinically and statistically significant electrocardiographic effects were seen at the higher dose levels (180 mg, 360 mg, and 600 mg). At the probable therapeutic dose (360 mg), concentration-effect modeling predicted the following changes at the time of maximum plasma concentration (30 minutes): Fridericia-corrected QT interval, 13.50 ms; heart rate (HR), 7.70 beats per minute; PR, 17.53 ms; QRS, 7.81 ms; P-wave duration, 9.93 ms; HR corrected J to T peak interval (JTpc), -9.65 ms; and T peak to T end interval, 5.07 ms.Peak plasma concentrations fell rapidly to negligible levels at 2 hours, associated with rapid redistribution from the central compartment. No significant adverse effects were observed, and no serious adverse events were reported. Conclusion: Sulcardine increased the QTc and PR intervals, QRS and P-wave durations, and HR dose dependently. The T-wave segment JTpc was significantly decreased, whereas the T peak to T end interval was significantly increased. These findings predict an anti-atrial fibrillation effect via inhibition of 1 or more cardiac ion channels. The strong block of the rapid component of the delayed rectifier potassium channel current was partially mitigated by JTp shortening, probably owing to late sodium current and L-type calcium current inhibition, reducing the risk of proarrhythmia by decreasing repolarization time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.